- Home
- WNEB vs IPHA Comparison
WNEB vs IPHA Comparison
Compare WNEB & IPHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | WNEB | IPHA |
|---|---|---|
| Founded | 1853 | 1999 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 270.5M | 169.6M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | WNEB | IPHA |
|---|---|---|
| Price | $13.01 | $1.75 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $11.00 | $5.00 |
| AVG Volume (30 Days) | ★ 42.1K | 21.6K |
| Earning Date | 01-28-2026 | 09-17-2025 |
| Dividend Yield | ★ 2.20% | N/A |
| EPS Growth | ★ 27.15 | N/A |
| EPS | ★ 0.66 | N/A |
| Revenue | ★ $79,080,000.00 | $14,839,695.00 |
| Revenue This Year | N/A | $22.29 |
| Revenue Next Year | $7.48 | $43.90 |
| P/E Ratio | $19.41 | ★ N/A |
| Revenue Growth | ★ 9.08 | N/A |
| 52 Week Low | $7.63 | $1.63 |
| 52 Week High | $13.95 | $2.63 |
Technical Indicators
Market Signals| Indicator | WNEB | IPHA |
|---|---|---|
| Relative Strength Index (RSI) | 51.10 | 51.09 |
| Support Level | $12.73 | $1.74 |
| Resistance Level | $13.44 | $1.85 |
| Average True Range (ATR) | 0.35 | 0.08 |
| MACD | 0.02 | 0.01 |
| Stochastic Oscillator | 51.64 | 62.50 |
Price Performance
Historical ComparisonAbout WNEB Western New England Bancorp Inc.
Western New England Bancorp Inc through its bank subsidiary, provides a range of financial services to individuals and companies in western Massachusetts and northern Connecticut. These services include commercial lending, residential lending and consumer lending, checking, savings and time deposits, cash management, and wealth management. Substantially all of the company's revenues, profits, and assets are derived by the Bank from banking products and services.
About IPHA Innate Pharma S.A. ADS
Innate Pharma SA is a clinical-stage biotechnology company. It is engaged in developing immunotherapies for cancer patients. Its approach is to harness the innate immune system through therapeutic antibodies and its ANKET (Antibody-based NK cell Engager Therapeutics) proprietary platform. The company's revenue results from payments received to research, collaboration, and licensing agreements signed with pharmaceutical companies. Its product pipeline includes lacutamab, monalizumab, IPH5201, IPH5301, IPH6101, IPH62, IPH6401 and IPH6501.